PR

MEZOO, connecting health through technology
Sharing MEZOO’s technology and vision.
External
2025.12.21
Mezoo Sees Threefold Revenue Growth This Year… IPO Outlook Brightens Next Year

 

Developer of Mobile Remote Patient Monitoring Solution

 

Passes KOSDAQ Technology Special Listing Preliminary Review

 

Adopted by 53% of Tertiary Hospitals… Expanding Overseas

 

Mezoo, the developer of the mobile remote patient monitoring (aRPM) solution HiCardi, is expected to see its revenue nearly triple year-on-year this year. This rapid growth is largely attributed to the swift expansion of its product supply to domestic hospitals through collaboration with Dong-A ST (170900). The company has also recently passed the preliminary review for a KOSDAQ technology special listing, signaling a positive outlook for its market debut next year. Mezoo plans to invest the proceeds from its public offering into global market expansion to further broaden its footprint.

 

A Mezoo official stated on the 21st, “We expect to achieve revenue of approximately KRW 80 billion this year, nearly three times higher than last year’s KRW 24 billion,” adding, “As the HiCardi series is rapidly building references at tertiary hospitals, we have set our revenue target for next year at KRW 150 billion.” While Mezoo’s revenue amounted to only several billion won in 2021, it has surged sharply since the company signed a domestic distribution agreement with Dong-A ST in 2022.



https://www.sedaily.com/NewsView/2H1TFC1AU0


 

적용 법률 및 규정
의료기기

하이카디® 시스템은 인허가에 따라 신생아, 소아, 청소년, 18세 이상 환자의 ECG 데이터를 측정하여 부정맥을 진단하는 의료기기로서 의료전문가가 사용하도록 설계되었습니다. 한국 KFDA로부터 의료기기 2등급 인증을 받았습니다. 유럽의료기기 지침(2007/47/EC에 따라 개정된 MDD 93/42/EEC)에 따라 준수된 Class IIb (CE2265). 의료기기 제품으로 CE 승인되었습니다. 미국 FDA는 Class II 510K로 승인 완료 예정입니다.

경고

본 자료는 의료 전문가에게만 배포되며 관련 사진과 함께 제공되는 자료와 관련하여 그 어떤 법적인 책임을 갖지 않습니다. 사용 전 사용 지침서를 주의 깊게 읽으십시오.